{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:31:59Z","timestamp":1790757119250,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012620","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000}}],"reference-count":263,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012620.pub2","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T16:48:06Z","timestamp":1544114886000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis"],"prefix":"10.1002","volume":"2018","author":[{"given":"Yuji","family":"Oba","sequence":"first","affiliation":[{"name":"University of Missouri; Division of Pulmonary and Critical Care Medicine; Columbia MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Keeney","sequence":"additional","affiliation":[{"name":"University of Bristol; Population Health Sciences, Bristol Medical School; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namratta","family":"Ghatehorde","sequence":"additional","affiliation":[{"name":"University of Missouri; Division of Pulmonary and Critical Care Medicine; Columbia MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"University of York; Centre for Reviews and Dissemination; Heslington York UK YO10 5DD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease","volume":"146","author":"Aaron","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1183\/09031936.00054213","article-title":"A comparison of the efficacy and safety of once-daily fluticasone furoate\/vilanterol with twice-daily fluticasone propionate\/salmeterol in moderate to very severe COPD","volume":"43","author":"Agust\u00ed","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0003|cit3","unstructured":"GSK113107 A 12-week study to evaluate the 24 hour pulmonary function of fluticasone furoate (FF)\/vilanterol inhalation powder (FF\/VI inhalation powder) once daily compared with salmeterol\/fluticasone propionate (FP) inhalation powder twice daily in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-113107-clinical-study-report-redact-v02.pdf"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15412550903140881","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50) on COPD exacerbations and impact on patient outcomes","volume":"6","author":"Anzueto","year":"2009","journal-title":"COPD"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0005|cit5","unstructured":"GSK100250 A randomized, double-blind, parallel group, 52-week study to compare the effect of fluticasone propionate\/salmeterol Diskus combination product 250\/50mcg bid with salmeterol diskus 50mcg bid on the annual rate of moderate\/severe exacerbations in subjects with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com\/files2\/gsk-sco100250-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Asai K Minakata Y Hirata K Fukuchi Y Kitawaki T Ikeda K QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study European Respiratory Society 23rd Annual Congress; 2013 September 7-11; Barcelona 2013","DOI":"10.1183\/13993003\/erj.42.Suppl_57.P3392"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0008|cit8","unstructured":"BI 205.137 A multiple dose comparison of tiotropium inhalation capsules, salmeterol inhalation aerosol and placebo in a six-month, double-blind, double-dummy, safety and efficacy study in patients with chronic obstructive pulmonary disease (COPD) trials.boehringer-ingelheim.com\/public\/trial_results_documents\/205\/205.137_U01-1231-02.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2466-11-51","article-title":"Efficacy and safety of inhaled formoterol 4.5 and 9 \u03bcg twice daily in Japanese and European COPD patients: phase III study results","volume":"11","author":"Bogdan","year":"2011","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0010|cit10","unstructured":"Boehringer Ingelheim International A multiple dose comparison of tiotropium inhalation capsules and salmeterol inhalation aerosol in a 12 week, randomized, double-blind, double-dummy, parallel group study in patients with chronic obstructive pulmonary disease (COPD) trials.boehringer-ingelheim.com\/public\/trial_results_documents\/205\/205.264_CO.pdf 03 FEB 2004"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.pupt.2005.02.013","article-title":"Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD","volume":"18","author":"Briggs","year":"2005","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0954-6111(03)00131-8","article-title":"Tolerance to bronchodilating effects of salmeterol in COPD","volume":"97","author":"Donohue","year":"2003","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0017|cit17","first-page":"157","article-title":"Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids","volume":"2","author":"Hodder","year":"2007","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","article-title":"Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD","volume":"38","author":"Buhl","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/thoraxjnl-2014-206345","article-title":"Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study","volume":"70","author":"Buhl","year":"2015","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"9356","key":"10.1002\/14651858.CD012620.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0025|cit25","unstructured":"GSK FCB3024 (Phase III) A multicentre, randomised, double-blind, parallel group study to compare the efficacy and safety of the salmeterol\/fluticasone combination product (50\/500mg strength) twice daily with salmeterol 50mg twice daily alone and fluticasone propionate 500mg twice daily alone, all delivered via the Diskus\/Accuhaler inhaler, in the treatment of patients with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com\/files2\/sfcb3024-clinical-study-report-redact-v02.pdf"},{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0027|cit27","unstructured":"GSKSCO30003 A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol\/fluticasone propionate (Seretide) 50\/500mcg BD, salmeterol 50mcg BD and fluticasone propionate 500mcg BD, all delivered via the Diskus tm\/Accuhaler tm inhaler, on mortality and morbidity of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment www.gsk-clinicalstudyregister.com\/files2\/gsk-sco30003-clinical-study-report-redact-v03.pdf"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.rmed.2010.09.008","article-title":"Beclomethasone\/formoterol in the management of COPD: a randomised controlled trial","volume":"104","author":"Calverley","year":"2010","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pupt.2006.06.001","article-title":"A pilot study to assess the effects of combining fluticasone propionate\/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD","volume":"20","author":"Cazzola","year":"2007","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"14","key":"10.1002\/14651858.CD012620.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study","volume":"17","author":"Chapman","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0031|cit31","unstructured":"NCT02055352 24-week study to evaluate efficacy and safety of the combination budesonide \/indacaterol vs fluticasone \/salmeterol in patients with COPD (COMBINE) clinicaltrials.gov\/ct2\/show\/NCT02055352"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0032|cit32","unstructured":"NCT01762800 Evaluating the control of COPD symptoms in patients treated with tiotropium bromide 18mcg once daily alone, ADOAIR 50\/250mcg twice daily alone or ADOAIR 50\/250mcg plus tiotropium bromide 18mcg clinicaltrials.gov\/ct2\/show\/NCT01762800"},{"issue":"11","key":"10.1002\/14651858.CD012620.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/COPD.S91407","article-title":"Efficacy and safety of fluticasone furoate\/vilanterol or tiotropium in subjects with COPD at cardiovascular risk","volume":"18","author":"Covelli","year":"2015","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0034|cit34","unstructured":"GSK 115805 A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate\/vilanterol (FF\/VI) inhalation powder 100\/25mcg once-daily via a novel dry powder inhaler compared with tiotropium bromide inhalation powder 18mcg delivered once-daily via the HandiHaler in subjects with chronic obstructive pulmonary disease (COPD) who have or are at risk for co-morbid cardiovascular disease gsk-clinicalstudyregister.com\/files2\/gsk-115805-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","volume":"15","author":"D'Urzo","year":"2014","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0036|cit36","unstructured":"European Medicines Agency Assessment report - Duaklir Genuair (aclidinium bromide\/ formoterol fumarate dihydrate) www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003745\/WC500178415.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0037|cit37","unstructured":"The Federal Joint Committee (G-BA) in Germany Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in accordance with the German Social Code, Book Five (SGB V), section 35a aclidinium bromide\/formoterol www.english.g-ba.de\/downloads\/91-1028-156\/Aclidinium%20bromide_formoterol_en.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2017.02.008","article-title":"A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium\/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease","volume":"125","author":"D'Urzo","year":"2017","journal-title":"Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0042|cit42","unstructured":"GSk113360 A multicenter trial comparing the efficacy and safety of GSK573719\/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-113360-clinical-study-report-redact-v02.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0044|cit44","unstructured":"GSK113374 A multi-center trial comparing the efficacy and safety of GSK573719\/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-113374-clinical-study-report-redact-v02.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pupt.2010.01.003","article-title":"Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design","volume":"3","author":"Barnes","year":"2010","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0048|cit48","unstructured":"GSK113374 A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GSK573719\/GW642444 inhalation powder and the individual components delivered once-daily via a novel dry powder inhaler in subjects with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com\/files2\/gsk-113373-clinical-study-report-redact-v03.pdf"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","article-title":"Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations","volume":"109","author":"Donohue","year":"2015","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0050|cit50","unstructured":"GSK DB2114930 DB2114930: a randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium\/vilanterol compared with fluticasone propionate\/salmeterol over 12 weeks in subjects with COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-114930-clinical-study-report-redact.pdf"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","article-title":"Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations","volume":"109","author":"Donohue","year":"2015","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0052|cit52","unstructured":"GSK DB2114951 DB2114951: a randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy umeclidinium\/vilanterol compared with fluticasone propionate\/salmeterol over 12 weeks in subjects with COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-114951-protocol-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rmed.2016.05.007","article-title":"Long-term safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD","volume":"116","author":"Donohue","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0054|cit54","unstructured":"The Federal Joint Committee (G-BA) in Germany Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in accordance with the German Social Code, Book Five (SGB V), section 35a aclidinium bromide\/formoterol www.english.g-ba.de\/downloads\/91-1028-156\/Aclidinium%20bromide_formoterol_en.pdf"},{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.rmed.2014.05.008","article-title":"Efficacy and safety of once-daily fluticasone furoate\/vilanterol (100\/25 mcg) versus twice-daily fluticasone propionate\/salmeterol (250\/50 mcg) in COPD patients","volume":"108","author":"Dransfield","year":"2014","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0056|cit56","unstructured":"GSK HZC112352 A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate\/vilanterol (FF\/VI) inhalation powder 100\/25 mcg once daily compared with fluticasone propionate\/salmeterol inhalation powder 250\/50 mcg twice daily in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-112352-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0057|cit57","unstructured":"GSK HZC113109 A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate\/vilanterol (FF\/VI) inhalation powder 100\/25 mcg once daily compared with fluticasone propionate\/salmeterol inhalation powder 250\/50 mcg twice daily in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-113109-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0058|cit58","unstructured":"GSK RLV116974 A 12-week study to evaluate the 24-hour pulmonary function profile of fluticasone furoate\/vilanterol (FF\/VI) inhalation powder 100\/25 mcg once daily compared with fluticasone propionate\/salmeterol inhalation powder 250\/50 mcg twice daily in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-116974-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/COPD.S102494","article-title":"A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 \u03bcg compared with tiotropium 18 \u03bcg in patients with COPD","volume":"11","author":"Feldman","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0060|cit60","unstructured":"GSK573719 A randomized, blinded, double-dummy, parallel-group study to evaluate the efficacy and safety of umeclidinium (UMEC) 62.5 mcg compared with tiotropium 18 mcg in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-201316-clinical-study-report-redact.pdf"},{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.rmed.2008.04.019","article-title":"Effect of fluticasone propionate\/salmeterol (250\/50 microg) or salmeterol (50 microg) on COPD exacerbations","volume":"102","author":"Ferguson","year":"2008","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0062|cit62","unstructured":"GSK SCO40043 A randomized, double-blind, parallel group, 52-week study to compare the effect of fluticasone propionate\/salmeterol Diskus inhaler combination product 250\/50mcg twice daily with salmeterol Diskus inhaler 50mcg twice daily on the annual rate of moderate\/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-sco40043-clinical-study-report-redact.pdf"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"716","DOI":"10.15326\/jcopdf.3.4.2016.0131","article-title":"Long-term maintenance bronchodilation with indacaterol\/glycopyrrolate versus indacaterol in moderate-to-severe COPD patients: the FLIGHT 3 study","volume":"3","author":"Ferguson","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2017.09.002","article-title":"Effect of budesonide\/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study","volume":"132","author":"Ferguson","year":"2017","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0065|cit65","unstructured":"NCT02157935 Comparing the efficacy of Symbicort pMDI and formoterol Turbuhaler in reducing exacerbations in patients with chronic obstructive pulmonary disease (RISE) clinicaltrials.gov\/ct2\/show\/NCT02157935"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/resp.12090","article-title":"Budesonide\/formoterol via Turbuhaler versus formoterol via Turbuhaler in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results","volume":"18","author":"Fukuchi","year":"2013","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0067|cit67","unstructured":"NCT 01069289 Efficacy and safety study of Symbicort Turbuhaler versus Oxis Turbuhaler in chronic obstructive pulmonary disease (COPD) patients (SUMIRE) clinicaltrials.gov\/ct2\/show\/study\/NCT01069289"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0068|cit68","unstructured":"NCT01119937 Long term safety and tolerability of NVA237 versus tiotropium in Japanese patients (GLOW4) clinicaltrials.gov\/ct2\/show\/NCT01119937"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2012.12.020","article-title":"Influence of salmeterol\/fluticasone via single versus separate inhalers on exacerbations in severe\/very severe COPD","volume":"107","author":"Hagedorn","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0070|cit70","unstructured":"GSK FCA3007 A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulation of salmeterol 50mcg twice daily and fluticasone propionate 250mcg twice daily individually and in combination as compared to placebo in COPD patients www.gsk-clinicalstudyregister.com\/files2\/sfca3007-clinical-study-report-redact-v02.pdf"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 microg)\/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.rmed.2017.03.015","article-title":"Long-term safety and efficacy of glycopyrrolate\/formoterol metered dose inhaler using novel Co-Suspension\u2122 Delivery Technology in patients with chronic obstructive pulmonary disease","volume":"126","author":"Hanania","year":"2017","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000351116","article-title":"Effects of tiotropium and salmeterol\/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease","volume":"86","author":"Hoshino","year":"2013","journal-title":"Respiration"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/resp.12256","article-title":"Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients","volume":"19","author":"Hoshino","year":"2014","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pupt.2014.08.002","article-title":"Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair in chronic obstructive pulmonary disease","volume":"30","author":"Hoshino","year":"2015","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.rmed.2011.02.013","article-title":"Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD","volume":"105","author":"Jones","year":"2011","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0077|cit77","unstructured":"GSK DB2116961 Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC\/VI (umeclidinium\/vilanterol) in a fixed dose combination with indacaterol plus tiotropium in symptomatic subjects with moderate to very severe COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-116961-clinical-study-report-redact.pdf"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40268-016-0131-2","article-title":"Dual bronchodilator therapy with umeclidinium\/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial","volume":"16","author":"Kalberg","year":"2016","journal-title":"Drugs in R&D"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0081|cit81","unstructured":"NCT00929110 A 52-week treatment, randomized, double-blind, placebo-controlled, with open-label tiotropium, parallel-group study to assess the efficacy, safety, and tolerability of glycopyrronium bromide (NVA237) in patients with chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT00929110"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0082|cit82","unstructured":"GSK DB2116960 A randomized, double-dummy, parallel group, multicenter trial comparing the efficacy and safety of UMEC\/VI (a fixed combination of umeclidinium and vilanterol) with tiotropium in subjects with COPD who continue to have symptoms on tiotropium www.gsk-clinicalstudyregister.com\/files2\/gsk-116960-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/COPD.S119032","article-title":"Umeclidinium\/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study","volume":"12","author":"Kerwin","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","article-title":"Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Koch","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0086|cit86","unstructured":"GlaxoSmithKline A randomized, double-blind, double-dummy, parallel group 12-week comparison of the efficacy and safety of fluticasone propionate\/salmeterol hydrofluoroalkane 134a metered-dose-inhaler 230\/42mcg twice-daily with fluticasone propionate\/salmeterol diskus 250\/50mcg twice-daily in subjects with copd www.gsk-clinicalstudyregister.com\/files2\/adc111117-clinical-study-report-redact.pdf 2014"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1874306401004010086","article-title":"Safety and efficacy of fluticasone propionate\/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate\/salmeterol diskus in patients with chronic obstructive pulmonary disease","volume":"4","author":"Koser","year":"2010","journal-title":"Open Respiratory Medicine Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0088|cit88","unstructured":"GlaxoSmithKline A randomized, double-blind, placebo-controlled, parallel-group, trial evaluating the safety and efficacy of the Diskus formulations of salmeterol 50mcg twice daily and fluticasone propionate 500mcg twice daily individually and in combination as compared to placebo in COPD patients www.gsk-clinicalstudyregister.com\/files2\/gsk-sfca3006-clinical-study-report-redact-v02.pdf 2015"},{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0091|cit91","unstructured":"Novartis A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 \u03bcg once daily with open label tiotropium 18 \u03bcg once daily versus open label tiotropium 18 \u03bcg once daily in patients with moderate-to severe chronic obstructive pulmonary disease www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=3901 2011"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","article-title":"Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison","volume":"67","author":"Mahler","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0093|cit93","unstructured":"Novartis A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 \u03bcg once daily with open label tiotropium 18 \u03bcg once daily versus open label tiotropium 18 \u03bcg once daily in patients with moderate-to severe chronic obstructive pulmonary disease www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=3903 2011"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","article-title":"FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol\/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease","volume":"192","author":"Mahler","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","article-title":"FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol\/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease","volume":"192","author":"Mahler","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.03.015","article-title":"Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3)","volume":"115","author":"Mahler","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0097|cit97","unstructured":"GlaxoSmithKline A multicenter, trial comparing the efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg once daily with tiotropium 18 mcg once daily over 24 weeks in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-117115-clinical-study-report-redact.pdf"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","article-title":"Assessing short-term deterioration in maintenance-na\u00efve patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials","volume":"33","author":"Maleki-Yazdi","year":"2017","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","article-title":"Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD","volume":"151","author":"Martinez","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.chest.2016.11.028","article-title":"Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD","volume":"151","author":"Martinez","year":"2017","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0101|cit101","unstructured":"NCT00876694 A 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and efficacy of indacaterol (300 \u00b5g o.d.) using salmeterol (50 \u00b5g b.i.d.) as an active control in Japanese patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT00876694"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0102|cit102","unstructured":"NCT01536262 Japan long-term safety for tiotropium plus olodaterol clinicaltrials.gov\/ct2\/show\/NCT01536262"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0103|cit103","unstructured":"GSK ADC113874 A randomized, double-blind, parallel group, multicenter study of the effects of fluticasone propionate\/salmeterol combination product 250\/50mcg bid (Advair Diskus\u2122) in comparison to salmeterol 50mcg bid (Serevent Diskus\u2122) on the rate of exacerbations of COPD following hospitalization www.gsk-clinicalstudyregister.com\/files2\/gsk-113874-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12931-014-0105-2","article-title":"Fluticasone propionate\/salmeterol 250\/50 \u03bcg versus salmeterol 50 \u03bcg after chronic obstructive pulmonary disease exacerbation","volume":"15","author":"Ohar","year":"2014","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0105|cit105","unstructured":"GSK HZC115247 A 12 week study to evaluate the effect of fluticasone furoate (FF, GW685698)\/vilanterol (VI, GW642444) 100\/25 mcg inhalation powder delivered once daily via a novel dry powder inhaler (NDPI) on arterial stiffness compared with tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-115247-clinical-study-report-redact.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.13-2859","article-title":"Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate\/vilanterol with tiotropium","volume":"146","author":"Pepin","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1183\/09031936.00115308","article-title":"Anti-inflammatory effects of salmeterol\/fluticasone, tiotropium\/fluticasone or tiotropium in COPD","volume":"33","author":"Perng","year":"2009","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0108|cit108","first-page":"A438","article-title":"Efficacy and safety of IND\/GLY (indacaterol\/glycopyrronium) versus placebo and tiotropium in symptomatic patients with moderate-to-severe COPD: the 52-week RADIATE study","volume":"20 (suppl 3)","author":"Larbig","year":"2015","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0109|cit109","unstructured":"NCT01610037 Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in chronic obstructive pulmonary disease patients with moderate to severe airflow limitation clinicaltrials.gov\/ct2\/show\/NCT01610037"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0111|cit111","unstructured":"GSK 201315 A randomized, parallel-group, open-label study to evaluate the efficacy and safety of umeclidinium (UMEC) 62.5 mcg compared with glycopyrronium 44 mcg in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-201315-clinical-study-report-redact.pdf"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"00101","DOI":"10.1183\/23120541.00101-2015","article-title":"A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD","volume":"2","author":"Rheault","year":"2016","journal-title":"ERJ Open Research"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1183\/09031936.00126814","article-title":"INSTEAD: a randomised switch trial of indacaterol versus salmeterol\/fluticasone in moderate COPD","volume":"44","author":"Rossi","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5578\/tt.10778","article-title":"Compare the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease","volume":"64","author":"Sarac","year":"2016","journal-title":"Tuberk Toraks"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0115|cit115","unstructured":"GSK SCO100470 A multicentre, randomised, double-blind, parallel group, 24-week study to compare the effect of the salmeterol\/fluticasone propionate combination product 50\/250mcg, with salmeterol 50mcg both delivered twice daily via the Diskus\/Accuhaler inhaler on lung function and dyspnoea in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-sco100470-clinical-study-report-redact-v02.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0116|cit116","unstructured":"GSK SCO40034 A multicentre, randomised, double-blind, double dummy, parallel group 12-week exploratory study to compare the effect of the salmeterol\/fluticasone propionate combination product (Seretide\u2122) 50\/500mcg bd via the Diskus\u2122\/Accuhaler\u2122 inhaler with tiotropium bromide 18 mcg od via the HandiHaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/23678.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0117|cit117","unstructured":"GSK SCO40041 A randomized, double-blind, parallel-group clinical trial evaluating the effect of the fluticasone propionate\/salmeterol combination product 250\/50mcg twice daily via Diskus inhaler versus salmeterol 50mcg twice daily via Diskus inhaler on bone mineral density in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-sco40041-clinical-study-report-redact.pdf"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.rmed.2011.07.020","article-title":"Effect of budesonide\/formoterol pMDI on COPD exacerbations: a double-blind, randomized study","volume":"106","author":"Sharafkhaneh","year":"2012","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0119|cit119","unstructured":"European Medicines Agency Assessment report Duaklir Genuair www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003745\/WC500178415.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2466-14-178","article-title":"Efficacy and safety of aclidinium bromide\/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study","volume":"14","author":"Singh","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0121|cit121","unstructured":"The Federal Joint Committee (G-BA) Germany Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII - Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in accordance with the German Social Code, Book Five (SGB V), section 35a aclidinium bromide\/formoterol www.english.g-ba.de\/downloads\/91-1028-156\/Aclidinium%20bromide_formoterol_en.pdf"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium + olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respiratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium + olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respiratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","article-title":"Tiotropium + olodaterol shows clinically meaningful improvements in quality of life","volume":"109","author":"Singh","year":"2015","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0125|cit125","unstructured":"GSK DB2116134 DB2116134: a randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium bromide\/vilanterol compared with fluticasone propionate\/salmeterol over 12 weeks in subjects with COPD www.gsk-clinicalstudyregister.com\/files2\/gsk-116134-clinical-study-report-redact.pdf"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","article-title":"Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial","volume":"15","author":"Singh","year":"2015","journal-title":"BMC Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"14","key":"10.1002\/14651858.CD012620.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15412550902724073","article-title":"Formoterol and tiotropium compared with tiotropium alone for treatment of COPD","volume":"6","author":"Tashkin","year":"2009","journal-title":"COPD"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0130|cit130","first-page":"73","article-title":"Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials","volume":"7","author":"Tashkin","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/COPD.S27320","article-title":"Effects of mometasone furoate\/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week phase III trial in subjects with moderate-to-very severe COPD","volume":"7","author":"Doherty","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0132|cit132","first-page":"73","article-title":"Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials","volume":"7","author":"Tashkin","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0133|cit133","first-page":"73","article-title":"Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials","volume":"7","author":"Tashkin","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.rmed.2012.09.002","article-title":"Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population","volume":"106","author":"To","year":"2012","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"e010106","DOI":"10.1136\/bmjopen-2015-010106","article-title":"Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design","volume":"6","author":"Troosters","year":"2016","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/COPD.S51592","article-title":"Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study","volume":"9","author":"Vincken","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"11","key":"10.1002\/14651858.CD012620.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009157","article-title":"Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease","author":"Chong","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","article-title":"Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study","volume":"1","author":"Vogelmeier","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","article-title":"Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study","volume":"48","author":"Vogelmeier","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0142|cit142","unstructured":"NCT 01985334 Study to evaluate the efficacy and safety of glycopyrronium or indacaterol maleate and glycopyrronium bromide fixed-dose combination regarding symptoms and health status in patients with moderate COPD switching from treatment with any standard COPD regimen clinicaltrials.gov\/ct2\/show\/NCT01985334"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12931-017-0622-x","article-title":"Efficacy and safety of direct switch to indacaterol\/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial","volume":"18","author":"Vogelmeier","year":"2017","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0144|cit144","unstructured":"GlaxoSmithKline SCO40036 Multicentre, randomised, double-blind, double dummy, parallel group, 104-week study to compare the effect of the salmeterol\/fluticasone propionate combination product (Seretide*) 50\/500mcg delivered twice daily via the Diskus*\/Acchuhaler* inhaler with tiotropium bromide 18 mcg delivered once daily via the HandiHaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com\/files2\/gsk-sco40036-clinical-study-report-redact.pdf"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0146|cit146","unstructured":"EudraCT 2009-013256-69 A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110\/50 \u03bcg o.d.) vs NVA237 (50 \u03bcg o.d.) and open-label tiotropium (18 \u03bcg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD) www.clinicaltrialsregister.eu\/ctr-search\/trial\/2009-013256-69\/AT#B"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012620.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.rmed.2014.05.013","article-title":"Extrafine beclomethasone\/formoterol in severe COPD patients with history of exacerbations","volume":"108","author":"Wedzicha","year":"2014","journal-title":"Respiratory Medicine"},{"issue":"23","key":"10.1002\/14651858.CD012620.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD012620.pub2-BIB0150|cit150","first-page":"1491","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"New Egyptian Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/resp.12211","article-title":"Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study","volume":"19","author":"Yao","year":"2014","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0152|cit152","first-page":"1015","article-title":"LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD","volume":"10","author":"Zhong","year":"2015","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","article-title":"Efficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active-controlled studies","volume":"9","author":"ZuWallack","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0156|cit156","unstructured":"NCT01559116 Characterization of 24-hour lung function profiles of inhaled tiotropium + olodaterol fixed dose combination in patients suffering from chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT01559116"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0157|cit157","unstructured":"NCT00696020 Combination of orally inhaled bi1744cl\/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). Randomised, double-blind, parallel group study to assess the efficacy and safety of 4 weeks of once daily treatment of 3 doses of orally inhaled bi 1744 cl, each in fixed dose combination with 5 microgram tiotropium bromide (delivered by the Respimat inhaler) compared with 5 microgram tiotropium bromide monoproduct (delivered by the Respimat inhaler) in patients with COPD clinicaltrials.gov\/ct2\/show\/NCT00696020"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0158|cit158","unstructured":"Boehringer Ingelheim A randomised, placebo-controlled, double-blind, single dose, cross-over study to evaluate the efficacy and safety of orally inhaled tiotropium + olodaterol as both a fixed dose combination and a free combination (both delivered by the Respimat inhaler) in patients with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT02030535"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0159|cit159","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies","volume":"5","author":"Bateman","year":"2010","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.rmed.2014.01.006","article-title":"Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study","volume":"108","author":"Beeh","year":"2014 Apr","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/COPD.S95055","article-title":"The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study)","volume":"11","author":"Beeh","year":"2016","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/S1806-37562015000000334","article-title":"Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study","volume":"42","author":"Berton","year":"2016","journal-title":"Jornal Brasileiro de Pneumologia"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1378\/chest.13-1579","article-title":"Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study","volume":"145","author":"Celli","year":"2014","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0164|cit164","unstructured":"Novartis Pharmaceuticals A 12 week, multi-center, randomized, open label study, evaluating the efficacy and safety of treatment regimens that include Onbrez (indacaterol) in patients with moderate to severe COPD (MOVE-ON Study) clinicaltrials.gov\/ct2\/show\/NCT01232894"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0165|cit165","unstructured":"Novartis Pharmaceuticals A randomized, double-blind, 12-week treatment, parallel-group study to evaluate the efficacy and safety of QMF149 (150 \u00b5g\/160 \u00b5g o.d.) compared with salmeterol xinafoate\/fluticasone propionate (50 \u00b5g\/500 \u00b5g b.i.d.) in patients with chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT01636076"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/15412555.2013.791809","article-title":"One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD","volume":"10","author":"D'Urzo","year":"2013","journal-title":"COPD"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/COPD.S49615","article-title":"Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study","volume":"8","author":"Dahl","year":"2013","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1465-9921-15-78","article-title":"Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study","volume":"15","author":"Donohue","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","article-title":"Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials","volume":"112","author":"Donohue","year":"2016","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012620.pub2-BIB0171|cit171","first-page":"811","article-title":"Combination of inhaled salmeterol\/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"31","author":"Fang","year":"2008","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","article-title":"Efficacy and safety of olodaterol once daily delivered via Respimat in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Ferguson","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.rmed.2013.07.001","article-title":"Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD","volume":"107","author":"Gelb","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0174|cit174","unstructured":"GlaxoSmithKline A 24-week study to evaluate the effect of fluticasone furoate\/vilanterol 100\/25 mcg inhalation powder delivered once-daily via a novel dry powder inhaler on arterial stiffness compared with placebo and vilanterol in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT01336608"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12931-016-0372-1","article-title":"The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month phase III studies","volume":"17","author":"Jones","year":"2016","journal-title":"Respiratory Research"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/15412555.2012.661492","article-title":"Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)","volume":"9","author":"Kerwin","year":"2012","journal-title":"COPD"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","article-title":"A randomised trial of fluticasone furoate\/vilanterol (50\/25 \u03bcg; 100\/25 \u03bcg) on lung function in COPD","volume":"107","author":"Kerwin","year":"2013","journal-title":"Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1843.2008.01452.x","article-title":"Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone","volume":"14","author":"Kurashima","year":"2009","journal-title":"Respirology"},{"issue":"18","key":"10.1002\/14651858.CD012620.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1183\/13993003.02165-2015","article-title":"A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol","volume":"48","author":"Pascoe","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.rmed.2012.05.011","article-title":"Effect of combination treatment on lung volumes and exercise endurance time in COPD","volume":"106","author":"Magnussen","year":"2012","journal-title":"Respiratory Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0184|cit184","unstructured":"Mahmud AM Gupta DK Khan AS Hassan R Hossain A Rahman M Comparison of once daily tiotropium with twice daily salmeterol in Bangladeshi patients with moderate COPD Respirology 2007 12 (Supple 4) A211"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0185|cit185","unstructured":"Make BJ Donohue JF Soong W Zhong X Leselbaum A Caracta C Lung function and safety of aclidinium bromide\/formoterol fumarate fixed-dose combination: results of a 1-year trial in patients with COPD American Journal of Respiratory and Critical Care Medicine 2014 A6010"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0186|cit186","unstructured":"GlaxoSmithKline An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719\/GW642444. Study A (COPD) clinicaltrials.gov\/ct2\/show\/NCT01328444"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0187|cit187","unstructured":"GlaxoSmithKline An exercise endurance study to evaluate the effects of treatment of chronic obstructive pulmonary disease (COPD) patients with a dual bronchodilator: GSK573719\/GW642444.Study B (COPD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01323660"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"175346581875509","DOI":"10.1177\/1753465818755091","article-title":"Effect of 12 weeks of once-daily tiotropium\/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease","volume":"12","author":"Maltais","year":"2018","journal-title":"Therapeutic Advances in Respiratory Disease"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 \u03bcg) improves lung function in COPD: a randomised trial","volume":"107","author":"Martinez","year":"2013","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0190|cit190","unstructured":"Boehringer Ingelheim A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC) (2.5 \/ 5 \u00b5g; and 5 \/ 5 \u00b5g) (delivered by the Respimat inhaler) compared with tiotropium (5 \u00b5g), olodaterol (5 \u00b5g ) and placebo (delivered by the Respimat inhaler) on lung hyperinflation and exercise endurance time during constant work rate cycle ergometry in patients with chronic obstructive pulmonary disease (COPD) [MORACTO TM 1] clinicaltrials.gov\/ct2\/show\/NCT01533922"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0191|cit191","unstructured":"Boehringer Ingelheim A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC) (2.5 \/ 5 \u00b5g; and 5 \/ 5 \u00b5g) (delivered by the Respimat inhaler) compared with tiotropium (5 \u00b5g), olodaterol (5 \u00b5g ) and placebo (delivered by the Respimat inhaler) on lung hyperinflation and exercise endurance time during constant work rate cycle ergometry in patients with chronic obstructive pulmonary disease (COPD) [MORACTO TM 2] clinicaltrials.gov\/ct2\/show\/NCT01533935"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0192|cit192","unstructured":"Pearl Therapeutics An open-label, multi-center, dose indicator study of glycopyrronium and formoterol fumarate (GFF) metered dose inhaler (MDI) in adult subjects with moderate to very severe chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT02268396"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1378\/chest.07-2138","article-title":"Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD","volume":"134","author":"Rabe","year":"2008","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40261-013-0138-1","article-title":"ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients","volume":"33","author":"Rennard","year":"2013","journal-title":"Clinical Drug Investigation"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.rmed.2011.09.006","article-title":"Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium","volume":"106","author":"Rossi","year":"2012","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0196|cit196","unstructured":"GlaxoSmithKline Clinical evaluation Of GW815SF for chronic obstructive pulmonary disease (chronic bronchitis, emphysema) clinicaltrials.gov\/ct2\/show\/NCT00269126"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.rmed.2016.12.001","article-title":"A randomised, phase III trial of once-daily fluticasone furoate\/vilanterol 100\/25 \u03bcg versus once-daily vilanterol 25 \u03bcg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD","volume":"123","author":"Siler","year":"2017","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.rmed.2016.03.018","article-title":"The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: a randomised crossover study (the TRIDENT study)","volume":"114","author":"Singh","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.rmed.2016.09.012","article-title":"A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate\/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD","volume":"120","author":"Tashkin","year":"2016","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0200|cit200","unstructured":"To Y Nishimura M Fukuchi Y Kitawaki T Okino N Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52-week open-labeled study Respirology. Conference: 16th Congress of the Asian Pacific Society of Respirology 2011 16:96"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.rmed.2010.02.017","article-title":"Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms","volume":"104","author":"Noord","year":"2010","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0202|cit202","first-page":"387","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"30","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.pupt.2010.04.005","article-title":"Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients","volume":"23","author":"Vogelmeier","year":"2010","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0204|cit204","first-page":"135","article-title":"Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium","volume":"11","author":"Vogelmeier","year":"2010","journal-title":"Respiration Physiology"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rmed.2012.09.015","article-title":"Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy na\u00efve patients","volume":"107","author":"Vogelmeier","year":"2013","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12890-016-0256-7","article-title":"Effects of indacaterol\/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)","volume":"16","author":"Watz","year":"2016","journal-title":"BMC Pulmonary Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/thx.2004.034280","article-title":"Withdrawal of fluticasone propionate from combined salmeterol\/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial","volume":"60","author":"Wouters","year":"2005","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/COPD.S81053","article-title":"Efficacy and safety of once-daily inhaled umeclidinium\/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study","volume":"10","author":"Zheng","year":"2015","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018 May","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.2147\/COPD.S136527","article-title":"Fluticasone propionate\/formoterol for COPD management: a randomized controlled trial","volume":"12","author":"Papi","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0211|cit211","unstructured":"AstraZeneca A 24 week treatment, multicenter, randomized, double blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 \u03bcg\/formoterol fumarate 12 \u03bcg fixed-dose combination bid compared with each monotherapy (aclidinium bromide 400 \u03bcg bid and formoterol fumarate 12 \u03bcg bid) and tiotropium 18 \u03bcg qd when administered to patients with stable chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT02796677"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0212|cit212","doi-asserted-by":"crossref","unstructured":"Sethi S Kerwin EM Watz H Ferguson GT Mroz R Segarra R AMPLIFY: A randomized, phase III study evaluating the efficacy and safety of aclidinium\/formoterol versus monotherapy in patients with COPD American Journal of Respiratory and Critical Care Medicine 2018 A4241","DOI":"10.2147\/COPD.S189138"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0213|cit213","unstructured":"AstraZeneca A 24-week treatment, randomised, parallel-group, double blinded, double-dummy, multicenter study to assess the efficacy and safety of aclidinium bromide\/formoterol fumarate compared with individual components and placebo and aclidinium bromide compared with placebo when administered to patients with stable chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT03022097"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0214|cit214","unstructured":"Frith P Ashmawi S Krishnamurthy S Diaz D Gurgun A Hours-Zesiger P Assessing direct switch to indacaterol\/glycopyrronium from salmeterol\/fluticasone in moderate to severe symptomatic COPD patients: the FLASH Study Respirology 2017 AOL011"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0215|cit215","unstructured":"Novartis Pharmaceuticals Assessment of switching from salmeterol\/fluticasone to indacaterol\/glycopyrronium in a symptomatic COPD patient cohort (FLASH) clinicaltrials.gov\/ct2\/show\/NCT02516592"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0216|cit216","unstructured":"Mundipharma Research A randomised double-blind, double-dummy parallel group study to compare the efficacy and safety of fluticasone propionate \/ formoterol fumarate (Flutiform) 500\/20 \u00b5g bid and 250\/10 \u00b5g bid versus salmeterol \/ fluticasone (Seretide) 50\/500 \u00b5g bid in subjects with chronic obstructive pulmonary disease (COPD) clinicaltrials.gov\/ct2\/show\/NCT02195375"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0217|cit217","unstructured":"Pearl Therapeutics A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multi-center study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD, compared with placebo clinicaltrials.gov\/ct2\/show\/NCT02343458"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0218|cit218","unstructured":"Pearl Therapeutics A randomized, double-blind, parallel-group, 24-week, chronic-dosing, multi-center study to assess the efficacy and safety of PT010, PT003, and PT009 compared with Symbicort Turbuhaler as an active control in subjects with moderate to very severe chronic obstructive pulmonary disease clinicaltrials.gov\/ct2\/show\/NCT02497001"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/resp.13100","article-title":"Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Chen","year":"2017","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"Decramer","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decision Making"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0226|cit226","doi-asserted-by":"crossref","DOI":"10.1002\/9781118951651","volume-title":"Network Meta-Analysis for Decision-Making","author":"Dias","year":"2018"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","article-title":"Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations","volume":"109","author":"Donohue","year":"2015","journal-title":"Respiratory Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD012620.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1513\/pats.200707-096ET","article-title":"Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease","volume":"5","author":"Falk","year":"2008","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0230|cit230","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008989.pub3","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","author":"Farne","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0231|cit231","unstructured":"2018 Global strategy for prevention, diagnosis and management of COPD goldcopd.org\/gold-reports\/"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0232|cit232","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"12","key":"10.1002\/14651858.CD012620.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0235|cit235","first-page":"428","article-title":"The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease","volume":"3","author":"Heidari","year":"2012","journal-title":"Caspian Journal of Internal Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012620.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0237|cit237","unstructured":"Higgins JP Altman DG Sterne JA (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0238|cit238","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012066.pub2","article-title":"Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)","author":"Horita","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0239|cit239","first-page":"1863","article-title":"Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis","volume":"10","author":"Huisman","year":"2015","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0240|cit240","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010844.pub2","article-title":"Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis","author":"Kew","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0241|cit241","first-page":"A5589","article-title":"Involvement of regulation of KCa channels via Gi, Gs in the synergistic action between anticholinergic agents and \u03b22-adrenergic receptor agonists in airway smooth muscle","volume":"189","author":"Kume","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jama.2009.1242","article-title":"Comparison of registered and published primary outcomes in randomized controlled trials","volume":"302","author":"Mathieu","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0243|cit243","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003793.pub3","article-title":"Pulmonary rehabilitation for chronic obstructive pulmonary disease","author":"McCarthy","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD012620.pub2-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012620.pub2-BIB0245|cit245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006829.pub2","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","author":"Nannini","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","article-title":"Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis","volume":"71","author":"Oba","year":"2016","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD012620.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/15412555.2016.1170799","article-title":"Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting \u03b2-agonist for COPD: a meta-analysis","volume":"13","author":"Oba","year":"2016","journal-title":"COPD"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/COPD.S57157","article-title":"Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States","volume":"9","author":"Patel","year":"2014","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0250|cit250","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"11","key":"10.1002\/14651858.CD012620.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201510-1966ST","article-title":"ATS\/ERS Task Force on Policy in Pulmonary Rehabilitation. An official American Thoracic Society\/European Respiratory Society policy statement. Enhancing implementation, use, and delivery of pulmonary rehabilitation","volume":"192","author":"Rochester","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","article-title":"LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis","volume":"12","author":"Rodrigo","year":"2017","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"2","key":"10.1002\/14651858.CD012620.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1753465815624612","article-title":"Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting \u03b22-agonists: a systematic review and network meta-analysis","volume":"10","author":"Schlueter","year":"2016","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","article-title":"Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial","volume":"15","author":"Singh","year":"2015","journal-title":"BMC Pulmonary Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012620.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"Journal of the Royal Statistical Society. Series B (Statistical Methodology)"},{"issue":"11","key":"10.1002\/14651858.CD012620.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/thoraxjnl-2011-201518","article-title":"Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality","volume":"67","author":"Suissa","year":"2012","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD012620.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"e009183","DOI":"10.1136\/bmjopen-2015-009183","article-title":"Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis","volume":"5","author":"Tricco","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1002\/14651858.CD012620.pub2-BIB0258|cit258","first-page":"E37","article-title":"Influenza vaccination in the elderly: why are the overall benefits still hotly debated?","volume":"56","author":"Trucchi","year":"2015","journal-title":"Journal of Preventive Medicine and Hygiene"},{"issue":"3","key":"10.1002\/14651858.CD012620.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"issue":"suppl 59","key":"10.1002\/14651858.CD012620.pub2-BIB0260|cit260","first-page":"PA2960","article-title":"Efficacy of aclidinium\/formoterol fixed-dose combination versus salmeterol\/fluticasone in COPD","volume":"46","author":"Vogelmeier","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD012620.pub2-BIB0261|cit261","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007891.pub3","article-title":"Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease","author":"Welsh","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0262|cit262","unstructured":"World Health Organization Chronic obstructive pulmonary disease. Burden of COPD www.who.int\/respiratory\/copd\/burden\/en\/"},{"key":"10.1002\/14651858.CD012620.pub2-BIB0263|cit263","unstructured":"Medical Research Council (MRC) WinBUGS 2007"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012620.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:54:30Z","timestamp":1775296470000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012620.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":263,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012620.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]}}}